相关临床试验
1959
391 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1884
Unknown
3
0.1%
已完成
1128
57.6%
Enrolling By Invitation
7
0.4%
尚未招募
6
0.3%
No Longer Available
3
0.1%
终止
67
3.4%
招募中
325
16.6%
Available
1
0.1%
撤回
41
2.1%
进行中（未招募）
378
19.3%
暂无批准数据
- At the TIME100 Health Leadership Forum in New York, oncology experts named vaccines, immunotherapy, early detection and prevention as the most promising fronts in cancer research. - American Cancer Society CEO Shane Jacobson credited philanthropic and federal funding for rapid innovation, citing Moderna and Merck's encouraging mRNA cancer vaccine results. - Memorial Sloan Kettering oncologist Andrea Cercek cited a 2024 rectal cancer study in which no patient had detectable tumors after six months of immunotherapy. - Cercek said she is 'very close' to extending this immunotherapy approach to other cancers, and predicted early detection and prevention will ultimately cure cancer.
- Mitsui & Co. has entered a service agreement with Singapore-based Oncoshot to use its AI-powered clinical data analysis technology for oncology real-world data. - The initiative will connect oncology specialists across the IHH Healthcare network and Asia-Pacific with Memorial Sloan Kettering Cancer Center via the MSK iHub accelerator. - Oncoshot's federated platform anonymizes and structures hospital data into research-ready datasets without moving data outside the institution, addressing privacy and governance limits. - Partners aim to standardize oncology clinical data, shorten clinical study timelines, and generate evidence from diverse Asian patient populations currently underrepresented in research.
- Pyxis Oncology reported updated Phase 1 data for micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. - In 33 efficacy-evaluable patients dosed at 5.4 mg/kg with a dose cap, MICVO achieved a 36% confirmed objective response rate and 94% disease control rate. - Median progression-free survival reached 6.2 months with a 79% 12-month overall survival probability, and no new safety signals were observed in 35 safety-evaluable patients. - The company plans to initiate the pivotal Phase 3 Headliner trial in mid-2027 after FDA and EMA alignment on dose selection and study design.
- The FDA granted Breakthrough Therapy Designation to JBS-003 (18F-fluoromisonidazole), a first-in-class hypoxia PET tracer, for guiding de-escalated radiation therapy in HPV-positive oropharyngeal carcinoma. - Long-term data from the 30 ROC program showed five-year overall survival of 97% in non-hypoxic patients receiving de-escalated 30 Gray radiation, matching the 97% seen with standard 70 Gray. - Approximately 75–80% of patients have non-hypoxic tumors and may safely undergo a greater than 50% radiation dose reduction, potentially sparing them from severe, permanent morbidity. - The ongoing randomized, double-blind Phase 3 trial (NCT06563479) is expected to reach primary completion in early 2028, with a target regulatory filing window in late 2029.
- A personalized mRNA vaccine combined with the immunotherapy drug Keytruda reduced the likelihood of melanoma returning or spreading compared with Keytruda alone, according to early clinical trial data. - Merck and Moderna tested the combination in melanoma patients whose tumors had been surgically removed, with the vaccine tailored to each individual's tumor. - Dr. Michael Postow, a medical oncologist at Memorial Sloan Kettering Cancer Center involved in the trial, described the treatment as promising. - Because the vaccine is personalized rather than melanoma-specific, researchers believe the same approach could potentially address other tumor types.
- A secondary analysis of the IMPROVE trial found that the digital Integrative Medicine@Home (IM@Home) program was associated with improved overall survival in patients with solid tumors undergoing systemic therapy. - At a median follow-up of 28.6 months, median overall survival was not reached in the IM@Home group versus 26.3 months in the control group, with 24-month survival rates of 69.1% versus 52.6% (P = .037). - In adjusted analyses accounting for tumor type and stage, IM@Home was associated with a lower risk of death (hazard ratio = 0.59), though the finding did not remain statistically significant in sensitivity analyses. - The authors caution that the survival analysis was exploratory and hypothesis-generating, warranting future trials specifically designed to evaluate survival outcomes.
- Foresite Labs has appointed Dr. Jorge Reis-Filho as Chief Strategy Officer and Operating Partner, with a concurrent role as Venture Partner at Foresite Capital. - Dr. Reis-Filho joins from AstraZeneca, where he served as Chief of AI for Science Innovation, Enterprise AI, leading AI initiatives to transform drug discovery and clinical development. - His appointment aims to translate advances in AI, machine learning, statistical genetics, and data science into new companies and platforms at the convergence of AI and life sciences. - Dr. Reis-Filho articulates a roadmap from AI agents to "AI innovators" and ultimately biomedical superintelligence, emphasizing validated discovery over retrieval and prediction.
- The phase III LITESPARK-011 trial showed belzutifan plus lenvatinib reduced the risk of disease progression or death by 30% versus cabozantinib monotherapy in previously treated advanced clear-cell renal-cell carcinoma. - The combination achieved a 53% objective response rate versus 40% for cabozantinib, with median progression-free survival of 14.8 months versus 10.7 months. - Overall survival showed a favorable trend (34.9 vs 27.6 months) but did not reach statistical significance, requiring longer follow-up for confirmation. - The findings position the belzutifan-lenvatinib combination as a potential new standard of care for patients whose disease progressed on prior immunotherapy.
- Memorial Sloan Kettering Cancer Center is leveraging artificial intelligence and large language models to extract clinical data from electronic health records at unprecedented scale, enabling insights across hundreds of thousands of patients. - The MSK-CHORD dataset harmonizes clinicogenomic data for all patients who have undergone tumor genomic profiling, a scale achievable only through AI-assisted curation rather than human chart review. - A machine learning algorithm that predicts cancer-associated blood clots has received an FDA investigational device exemption under the Software as a Medical Device pathway, a first for MSK. - MSK has sequenced tumors from over 100,000 patients using MSK-IMPACT, MSK-ACCESS, and MSK-TARGET platforms, with annotated clinical data available through cBioPortal to accelerate discovery.
- The Society of Hematologic Oncology (SOHO) has launched its second podcast, SOHO Spotlight, focused on educational content for hematologic malignancy management. - The podcast features leading global experts sharing practical tips and strategies on leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. - The inaugural episode features Dr. Jae Park and Dr. Nicholas Short discussing CAR T-cell therapy, including safer outpatient treatment and earlier lines of treatment. - Episodes are available on major platforms including Spotify, Amazon, YouTube, and Apple Podcasts.
